Maltofer, 30 pcs.

Maltofer contains iron in the form of a polymaltose complex of iron (III) hydroxide. This macromolecular complex is stable and does not release iron in the form of free ions in the gastrointestinal tract.

The structure of Maltofer® is similar to the natural iron compound – ferritin. Due to this similarity, iron (III) is taken from the intestine into the blood by active transport.

The absorbed iron is bound to ferritin and stored in the body, mainly in the liver. It is then incorporated into hemoglobin in the bone marrow.

The iron in the polymaltose complex of iron (III) hydroxide has no pro-oxidant properties, unlike simple iron salts.

There is a correlation between the severity of iron deficiency and the level of iron absorption (the greater the severity of iron deficiency, the better the absorption). The most active absorption process occurs in the duodenum and small intestine.

The drug Maltofer® does not cause staining of teeth enamel.

Indications

Latent iron deficiency and clinically pronounced iron deficiency (iron deficiency anemia); prevention of iron deficiency in women during pregnancy, breastfeeding, childbearing period, children, including teenagers.

In children, including adolescents, in adults (e.g. vegetarians and the elderly).

Composition

Active substance:

iron in the form of polymaltose complex of iron (III)hydroxide 100 mg;

Auxiliary substances:

dextrates;

vanillin;

sodium cyclamate;

talcum powder;

MacroGol 6000;

Chocolate flavoring;

Cocoa powder;

MCC;

How to take, the dosage

Ingestion.

Take with or immediately after meals. The daily dose of the drug depends on the degree of iron deficiency.

The duration of treatment of clinically expressed iron deficiency (iron deficiency anemia) is 3-5 months, until normalization of hemoglobin level.

Thereafter, the drug should be continued in the dosage for the treatment of latent iron deficiency for several more months, and for pregnant women, at least until delivery to restore iron reserves.

The duration of treatment of latent iron deficiency is 1-2 months.

In cases of clinically pronounced iron deficiency, normalization of hemoglobin levels and replenishment of iron reserves does not occur until 2-3 months after treatment begins.

Special Instructions

Notice for diabetics: One tablet contains 0.04 bread units.

No adverse effects on the fetus have been found during the first trimester of pregnancy.

Contraindications

Side effects

Gastrointestinal disorders: feeling of fullness, pressure in the epigastric region, nausea, constipation or diarrhea; dark staining of stools is possible due to excretion of unabsorbed iron, which is of no clinical significance.

Overdose

In cases of overdose of the drug, no signs of intoxication or signs of excessive iron intake have been described to date.

Pregnancy use

In controlled trials in pregnant women after the first trimester of pregnancy no adverse effects on the mother or fetus have been observed.

There were no adverse effects of the drug on the fetus during the first trimester of pregnancy.